GLENN PIERCE

LA JOLLA, CA

General Payments — all program years on this page

$5,243,778.33

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 104
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $37,129.97 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
BioMarin Pharmaceutical Inc. $18,511.3512
Novo Nordisk Health Care AG $14,124.624
Regeneron Pharmaceuticals, Inc. $4,494.003

By program year

Program yearAmountRecords
2018 $13,464.739
2019 $310.664
2020 $74,058.5918
2021 $9,561.279
2022 $5,085,296.0130
2023 $23,957.1015
2024 $37,129.9719

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096553580 Novo Nordisk Health Care AG $84.00 06/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096553656 Novo Nordisk Health Care AG $8,887.50 06/25/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1096553668 Novo Nordisk Health Care AG $4,453.00 06/25/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1096553882 Novo Nordisk Health Care AG $700.12 06/25/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114403727 Regeneron Pharmaceuticals, Inc. $749.00 03/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114403729 Regeneron Pharmaceuticals, Inc. $1,498.00 03/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114403731 Regeneron Pharmaceuticals, Inc. $2,247.00 04/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1127057815 BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1127057817 BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1127063124 BioMarin Pharmaceutical Inc. $6,600.00 11/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1127063126 BioMarin Pharmaceutical Inc. $894.22 09/30/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1127063130 BioMarin Pharmaceutical Inc. $47.04 11/14/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1127063132 BioMarin Pharmaceutical Inc. $60.39 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1127063134 BioMarin Pharmaceutical Inc. $73.08 11/14/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1127063136 BioMarin Pharmaceutical Inc. $4,620.91 06/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1127063138 BioMarin Pharmaceutical Inc. $71.85 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1127063140 BioMarin Pharmaceutical Inc. $52.68 11/14/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1127063142 BioMarin Pharmaceutical Inc. $92.40 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1127063146 BioMarin Pharmaceutical Inc. $64.42 11/14/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.